A new market study, titled “Stem Cell Therapy for Diabetes and Related Conditions – A Pipeline Analysis Report”, has been featured on wiseGuyReports.
Stem cell therapy for diabetes and related conditions: An insight
The stem cell therapy for diabetes and related conditions pipeline analysis report includes ongoing clinical and non-clinical trends in the global stem cell therapy for diabetes and related conditions treatment. Most of the pipeline therapeutics are in early stage of development, a long-lasting and less frequent dose can impact overall diabetes market.
In 2015, the American Diabetes Association (ADA) estimated that the annual total cost of diabetic patients is $223.5 billion in the US alone. The global annual cost is estimated at $465 billion and is expected to reach $510 billion a year by 2030.
Covered in this report
The report covers the present scenario and the growth prospects of the stem cell therapy for diabetes and related conditions. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
The Stem Cell Therapy for Diabetes and Related Conditions – A Pipeline Analysis Report, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects during the forecast period. The report also includes a discussion of the key companies operating in this market.
- Caladrius Biosciences
- Novo Nordisk
Key questions answered in this report
- How will the market evolve during the forecast period?
- What are the major parameters impacting the market?
- What are the key market trends?
- What are the challenges to market growth?
- Who are the key companies in this market space?
Table of Contents
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: STEM CELL THERAPY FOR DIABETES AND RELATED CONDITIONS: AN INSIGHT
PART 04: MAJOR REGULATORY AUTHORITIES
PART 05: PIPELINE LANDSCAPE
PART 06: COMPARATIVE ANALYSIS
- Mid-stage molecules (Phase II)
- Early-stage molecules (Phase I/II)
- Pre-clinical stage molecules
- Inactive and discontinued molecules
PART 07: INDICATION ANALYSIS
PART 08: THERAPEUTIC ASSESSMENT BY THERAPY TYPE
PART 09: THERAPEUTIC ASSESSMENT BY ROA
PART 10: KEY COMPANIES
- Active companies: Category and parameters
PART 11: APPENDIX
- List of abbreviations
Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)